LEADS BIOLABS' OPAMTISTOMIG (PD-L1/4-1BB BISPECIFIC ANTIBODY) NDA ACCEPTED BY NMPA, POISED TO BECOME WORLD'S FIRST APPROVED 4-1BB-TARGETING THERAPY

Reuters · 3d ago

Please log in to view news